论文部分内容阅读
11例脑胶质瘤和其他颅内占位者,经静脉注射~(131)Ⅰ标记抗人脑胶质瘤单克隆抗体SZ39,0.7～2.9mCi/100～300μg蛋白。然后 通过手术组织标本放射性强度测定,肿瘤SPECT扫描及血尿标本分析,研究SZ39在脑胶质瘤患者体内分布及药代动力学参数。结果提示,SZ39可在人脑胶质瘤内浓集,为脑组织的1.9～4.8倍,平均3.2倍。SPECT可清晰显示肿瘤图像,而非胶质瘤性颅内占位,未见肿瘤显像。抗体在肿瘤内浓集可持续2周以上。血液中的半清除期T1/2快相为1.6h,慢相为39h。所有患者临床观察无明显不良反应。以上初步研究结果显示,SZ39有进一步用于临床诊断与治疗的前景。
In 11 cases of gliomas and other intracranial occupying patients, 131I-labeled anti-human glioma monoclonal antibody SZ39 was intravenously injected, 0.7-2.9 mCi/100-300 μg of protein. Then the radioactive intensity of surgical tissue specimens, tumor SPECT scan and hematuria specimens were analyzed to study the distribution and pharmacokinetic parameters of SZ39 in glioma patients. The results suggest that SZ39 can be concentrated in human gliomas, which is 1.9-4.8 times of brain tissue, with an average of 3.2 times. SPECT can clearly show the tumor image instead of glioma intracranial space occupying and no tumor imaging. The concentration of antibodies in tumors can last for more than 2 weeks. The half-clearing period in the blood is 1.6h for the fast phase and 39h for the slow phase. All patients did not have clinically observed adverse reactions. The above preliminary results show that SZ39 has further prospects for clinical diagnosis and treatment.